Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
2
40%
Ph phase_2
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Other(2)

Detailed Status

Completed2
unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 32 (40.0%)

Trials by Status

completed240%
recruiting120%
unknown240%

Recent Activity

1 active trials
Showing 5 of 5
completedphase_3

Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)

NCT00478699
recruitingphase_3

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

NCT03919552
unknownphase_2

Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC

NCT01771289
completedphase_2

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

NCT01204307
unknownphase_1

Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer

NCT00982436

Clinical Trials (5)

Showing 5 of 5 trials
NCT00478699Phase 3

Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)

Completed
NCT03919552Phase 3

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Recruiting
NCT01771289Phase 2

Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC

Unknown
NCT01204307Phase 2

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Completed
NCT00982436Phase 1

Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5